SequelSEC

EXELIXIS, INC. EXEL

Biological Products, (No Diagnostic Substances) · CIK 0000939767 · Fiscal year ends 0101

Revenue
$2.32B
Fiscal year ended 2026-01-02
Operating income
$872.19M
Fiscal year ended 2026-01-02
Free cash flow
$875.84M
Fiscal year ended 2026-01-02

EXELIXIS, INC. (EXEL) reported revenue of $2.32B and net income of $782.57M for the fiscal year ended 2026-01-02. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from EXELIXIS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

EXELIXIS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-022025-01-032023-12-292022-12-302021-12-312021-01-012020-01-032018-12-282017-12-292016-12-31
Revenue$2.32B$2.17B$1.83B$1.61B$1.43B$987.54M$967.78MUnavailable$452.48M$191.45M
Cost of revenue$83.70M$76.22M$72.55M$57.91M$52.87M$36.27M$33.10MUnavailable$15.07M$6.55M
Gross profit$2.24B$2.09B$1.76B$1.55B$1.38B$951.27M$934.68MUnavailable$437.41M$184.90M
Operating income$872.19M$604.62M$170.88M$201.48M$286.67M$110.06M$369.47MUnavailable$165.91M-$28.12M
Net income$782.57M$521.27M$207.76M$182.28M$231.06M$111.78M$321.01MUnavailable$154.23M-$70.22M
Research & development$825.00M$910.41M$1.04B$891.81M$693.72M$547.85M$336.96MUnavailable$112.17M$95.97M
Weighted-average diluted sharesshares 281.86Mshares 296.13Mshares 321.46Mshares 324.56Mshares 322.36Mshares 318.00Mshares 315.01MUnavailableshares 312.00MUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable$130.84M$398.11MUnavailable$158.58M-$70.22M
Income tax expense$158.64M$160.37M$49.76M$52.07M$63.09M$19.06M$77.10MUnavailable$4.35M$0
Diluted EPS$2.78$1.76$0.65$0.56$0.72$0.35$1.02Unavailable$0.49Unavailable
Selling, general & administrative$518.73M$492.13M$542.70M$459.86M$401.72M$293.36M$228.24MUnavailable$159.33M$116.14M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

EXELIXIS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-022025-01-032023-12-292022-12-302021-12-312021-01-012020-01-032018-12-282017-12-292016-12-31
Cash & equivalents$482.49M$217.37M$262.99M$501.20M$647.17M$319.22M$266.50MUnavailable$183.16M$151.69M
Total assets$2.84B$2.95B$2.94B$3.07B$2.62B$2.14B$1.89BUnavailable$655.29M$595.74M
Current assets$1.44B$1.47B$1.32B$1.62B$1.83B$1.45B$1.01BUnavailable$484.87M$469.00M
Total liabilities$683.10M$703.49M$678.44M$583.06M$405.62M$258.22M$199.70MUnavailable$370.33M$506.42M
Current liabilities$405.64M$403.77M$394.28M$324.36M$337.59M$204.66M$142.75MUnavailable$115.17M$268.79M
Total equity incl. NCI$2.16B$2.24B$2.26B$2.49B$2.21B$1.88B$1.69BUnavailable$284.96M$89.32M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$21.69M$22.39M$17.32M$33.30M$27.49M$20.97M$12.89MUnavailable$6.66M$3.34M
Accounts receivable$286.92M$265.44M$237.41M$214.78M$282.65M$160.88M$119.07MUnavailable$77.30M$40.44M
Goodwill$63.68M$63.68M$63.68M$63.68M$63.68M$63.68M$63.68MUnavailable$63.68M$63.68M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$189.12M
Accounts payable$29.62M$38.19M$33.77M$32.67M$24.26M$23.63M$11.58MUnavailable$9.58M$6.56M

Cash flow

EXELIXIS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-022025-01-032023-12-292022-12-302021-12-312021-01-012020-01-032018-12-282017-12-292016-12-31
Operating cash flow$884.27M$699.97M$333.32M$362.61M$400.80M$208.98M$526.96MUnavailable$165.61M$206.30M
Capital expenditures$8.43M$28.44M$40.47M$27.71M$54.22M$30.34M$12.83MUnavailable$21.14M$1.70M
Investing cash flow$350.44M-$116.78M-$26.96M-$524.41M-$42.88M-$131.22M-$587.25MUnavailable$36.80M-$216.05M
Financing cash flow-$969.59M-$628.81M-$546.05M$586.00K-$14.80M-$25.13M$12.55MUnavailable-$169.93M$19.80M
Net change in cash$265.11M-$45.62M-$239.68M-$161.21M$343.12M$52.64M-$47.74MUnavailable$32.48M$10.05M
Stock-based compensation$112.98M$93.84M$106.34M$107.57M$119.82M$105.07M$56.60MUnavailable$23.94M$22.91M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$947.51M$652.03M$550.38M$0$0UnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$29.06M$28.80M$25.72M$20.88M$13.63M$9.14M$8.35MUnavailable$1.19M$1.00M

Derived

EXELIXIS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-01-022025-01-032023-12-292022-12-302021-12-312021-01-012020-01-032018-12-282017-12-292016-12-31
Free cash flow$875.84M$671.54M$292.86M$334.91M$346.58M$178.64M$514.12MUnavailable$144.47M$204.59M
Gross margin96.4%96.5%96.0%96.4%96.3%96.3%96.6%Unavailable96.7%96.6%
Operating margin37.6%27.9%9.3%12.5%20.0%11.1%38.2%Unavailable36.7%-14.7%
FCF margin37.7%31.0%16.0%20.8%24.2%18.1%53.1%Unavailable31.9%106.9%
SBC / revenue4.9%4.3%5.8%6.7%8.4%10.6%5.8%Unavailable5.3%12.0%
Current ratio3.56x3.63x3.34x4.99x5.43x7.06x7.08xUnavailable4.21x1.74x
Revenue YoY growth7.0%18.5%13.6%12.3%45.3%2.0%UnavailableUnavailable136.3%Unavailable
Net margin33.7%24.0%11.4%11.3%16.1%11.3%33.2%Unavailable34.1%-36.7%
R&D / revenue35.6%42.0%57.0%55.4%48.3%55.5%34.8%Unavailable24.8%50.1%
CapEx / revenue0.4%1.3%2.2%1.7%3.8%3.1%1.3%Unavailable4.7%0.9%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.12x
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable2.7%Unavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open EXEL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-02-10View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-07-28View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2018-12-28

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2018-12-28

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.